SALUBRISBIO
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

SALUBRISBIO Trademark

Serial Number: 87425888 • Registration: 5748146

SALUBRISBIO is a trademark filed by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. on April 26, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (10 trademarks)

37F, Main Tower, Lvjing Plaza,
Futian Dist. Shenzhen 518040 , CN

Entity Type: 99

Trademark Details

Filing Date

April 26, 2017

Registration Date

May 14, 2019

Published for Opposition

February 26, 2019

Cancellation Date

November 28, 2025

Goods & Services

Pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicines for human purpose, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biological preparations for medical purposes, namely, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biochemical medicines, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Drugs for medical purposes in the nature of medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Injections, namely, vaccines and injectable medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of components of finished pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Dietetic substances adapted for medical use, namely, dietetic beverages and food for medical purposes, the foregoing dietetic food and beverages containing vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, restoratives, plant fibre, nutrition powder, nutrient capsule, nutrient tablets, and containing mineral food-supplements, the foregoing dietetic foods and beverages are used for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases

Filing History

CANCELLED SEC. 8 (6-YR)
Nov 28, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 14, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
May 14, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 26, 2019 NPUB
PUBLISHED FOR OPPOSITION
Feb 26, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 6, 2019 NONP
NOTICE OF REINSTATEMENT MAILED
Jan 25, 2019 MREI
1(B) BASIS DELETED; NEW BASIS REQUESTED
Jan 23, 2019 ADBS
REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED
Jan 22, 2019 RGIA
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 22, 2019 AITU
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 17, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 17, 2018 ABN6
NOTICE OF ALLOWANCE CANCELLED
Nov 14, 2018 IUCN
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Oct 9, 2018 PCBG
ASSIGNED TO PETITION STAFF
Oct 5, 2018 APET
TEAS PETITION TO AMEND BASIS RECEIVED
Sep 24, 2018 TPAD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 22, 2018 EXRA
SOU EXTENSION 1 GRANTED
Sep 21, 2018 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 6, 2018 AITU
NOTICE OF REVIVAL - E-MAILED
Jul 18, 2018 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Jul 17, 2018 TPEX
PETITION TO REVIVE-GRANTED
Jul 17, 2018 PETG
TEAS PETITION TO REVIVE RECEIVED
Jul 17, 2018 PROA
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jun 18, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 18, 2018 ABN6
SOU EXTENSION 1 FILED
May 14, 2018 EXT1
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 14, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 19, 2017 NPUB
PUBLISHED FOR OPPOSITION
Sep 19, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 30, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 27, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 27, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 27, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 27, 2017 CNEA
ASSIGNED TO EXAMINER
Jul 24, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 3, 2017 NWOS
NEW APPLICATION ENTERED
Apr 29, 2017 NWAP